Navigation Links
Gentris Corporation Partners with BioFortis, Announces New Vice President of Information Technology
Date:9/25/2013

MORRISVILLE, N.C., Sept. 25, 2013 /PRNewswire/ -- Gentris® Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that it has partnered with BioFortis to integrate its Labmatrix™ and Qiagram™ software into Gentris' laboratory operations. The Labmatrix™ and Qiagram™ software will provide an advanced platform for clients to view and manage samples housed in the Gentris biorepository, while simultaneously enhancing their ability to collect, harmonize, and integrate multiple data sources, e.g., clinical, molecular, patient, and biospecimen data. In addition, Gentris has recently hired John Doyle as Vice President of Information Technology to lead the implementation of BioFortis' solution. John brings with him over 25 years of experience at IBM, which he will leverage as he continues to grow and enhance Gentris' IT infrastructure.

(Logo: http://photos.prnewswire.com/prnh/20130916/CL80771LOGO)

BioFortis is a leading provider of web-based, enterprise-class, scientific intelligence solutions for clinical and translational research. Its Labmatrix™ and Qiagram™ software were created to integrate and query disparate data from multiple sources including biomarker, translational, clinical, and healthcare data sets. This highly flexible platform allows for the seamless aggregation and exchange of existing and new data sets, making it accessible to multiple stakeholders. By combining Labmatrix™ ability to facilitate more efficient and effective analysis of scientific data across an organization with Gentris' biobanking and genomic biomarker services, the two companies can help pharmaceutical and biotechnology sponsors accelerate translational research and advance the application of personalized medicine to improve patient care.

"We are extremely excited to have the opportunity to partner with a cutting-edge company like BioFortis," said John Doyle, Gentris Vice President, Information Technology. "One of the biggest hurdles for large pharmaceutical and biotechnology companies looking to capitalize on the potential of genomic biomarkers and personalized medicine is the inability to integrate distributed data sources, legacy systems, and different data-types. Together, Gentris and BioFortis can help clients better manage their clinical samples, seamlessly incorporate genomic testing, and most importantly, effectively and efficiently convert the tremendous amount of data they collect into actionable information."

John Doyle was hired as Vice President of Information Technology to drive the evolution of Gentris' IT infrastructure and lead the implementation of the Labmatrix™ and Qiagram™ software. John served as a programmer at IBM for 14 years assuming increasing responsibilities before transitioning into a software engineer role in 2001. He has extensive experience in all phases of the software development lifecycle including the design, configuration, deployment, and implementation of Java Enterprise systems. Under John's leadership, Gentris will continue to improve its IT systems and infrastructure in order to meet client demands and expand the company's informatics and bioinformatics capabilities. John received his Bachelor's of Science degree in Computer and Information Science from Bloomsburg University of Pennsylvania. He received his Master's of Science degree in Computer and Information Science from Villanova University.

Related Links: www.gentris.com, www.biofortis.com

About Gentris Corporation:
Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs. The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally. In the past year, Gentris has significantly expanded its facility and onsite biorepository to meet the increased needs of biopharma clients, while maintaining a preeminent quality system.

About BioFortis:
BioFortis, Inc. is a software company focused on addressing the challenges in today's data-intensive environments. Founded in 2002 by transfer of the Labmatrix™ technology from The Johns Hopkins University School of Medicine, the company has since become a leading provider of information management solutions for the translational life science research community. Labmatrix has grown to support numerous organizations in a variety of application areas including translational clinical and genetic research, personalized medicine and biomarker studies, as well as biobanking.


'/>"/>
SOURCE Gentris Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bluechiip Signs Strategic Partnership with Gentris Corporation
2. Harwood Feffer LLP Announces Investigation of Verenium Corporation
3. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
4. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014
5. China Cord Blood Corporation to Report First Quarter of Fiscal 2014 Financial Results
6. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
7. Verenium Corporation To Announce Second Quarter 2013 Financial Results
8. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
9. Techne Corporation Announces Acquisition Completion
10. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
11. Hurel Corporation Launches Cell-Based In Vitro Testing Product Suite, Milestone in Movement Away from Use of Live Animals in Drug and Toxicity Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, president ... Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will be ... Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering and ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a fundamental ... samples to full-size tissues, bones, even whole organs to implant in people to ... blood deep into the developing tissue. , Current bioengineering techniques, including 3-D ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):